Arcutis Biotherapeutics Inc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $13.50 on 11/29/24, while the lowest value for the same period was recorded at $2.00 on 12/19/23.
52-week price history of ARQT Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Arcutis Biotherapeutics Inc’s current trading price is -4.11% away from its 52-week high, while its distance from the 52-week low is 547.25%. The stock’s price range during this period has spanned from $2.00 to $13.50. In the Healthcare sector, the Arcutis Biotherapeutics Inc’s shares surpassed a trading volume of approximately 1.19 million for the day, which was noticeably lower compared to the average daily volume of 9.2.01 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Arcutis Biotherapeutics Inc (ARQT) has experienced a quarterly rise of 27.41% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.52B and boasts a workforce of 296 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 10.03, with a change in price of +3.06. Similarly, Arcutis Biotherapeutics Inc recorded 2,061,373 in trading volume during the last 100 days, posting a change of +31.32%.
Examining ARQT’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ARQT stands at 1.33. Similarly, the long-term debt-to-equity ratio is also 0.69.
ARQT Stock Stochastic Average
Today’s raw stochastic average for Arcutis Biotherapeutics Inc over the last 50 days is 87.75%.This indicates a increase from the raw stochastic average of the past 20 days, which was 85.43%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 80.80% and 83.14%, respectively.
ARQT Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a gain of 300.77%.However, over the last six months, we can see a weaker performance of 50.00%. Over the last 30 days, the price of ARQT has fallen by 23.64%. And in the last five days, it has surged by 4.40%.
